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ABSTRACT
Antimicrobial therapy is facing a worrisome and underappreciated challenge, the phenomenon
of heteroresistance (HR). HR has been gradually documented in clinically relevant pathogens (e.g.
Pseudomonas aeruginosa, Staphylococcus aureus, Burkholderia spp., Acinetobacter baumannii,
Klebsiella pneumoniae, Candida spp.) towards several drugs and is believed to complicate the
clinical picture of chronic infections. This type of infections are typically mediated by polymicro-
bial biofilms, wherein microorganisms inherently display a wide range of physiological states, dis-
tinct metabolic pathways, diverging refractory levels of stress responses, and a complex network
of chemical signals exchange. This review aims to provide an overview on the relevance, preva-
lence, and implications of HR in clinical settings. Firstly, related terminologies (e.g. resistance, tol-
erance, persistence), sometimes misunderstood and overlapped, were clarified. Factors
generating misleading HR definitions were also uncovered. Secondly, the recent HR incidences
reported in clinically relevant pathogens towards different antimicrobials were annotated. The
potential mechanisms underlying such occurrences were further elucidated. Finally, the link
between HR and biofilms was discussed. The focus was to recognize the presence of heteroge-
neous levels of resistance within most biofilms, as well as the relevance of polymicrobial biofilms
in chronic infectious diseases and their role in resistance spreading. These topics were subject of
a critical appraisal, gaining insights into the ascending clinical implications of HR in antimicrobial
resistance spreading, which could ultimately help designing effective therapeutic options.
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Since the discovery of penicillin in the 1920s (Fleming
1929), we have become aware of how well microorgan-
isms find ways to circumvent every treatment thrown
their way. Antibiotics saved countless lives and took us
to a “golden era” of medicine, but the emergence of
antimicrobial resistance (AMR) quickly led us to a time
where previously treatable infections are becoming life-
threatening once again (Martens and Demain 2017;
CDC 2019). AMR has been increasingly impacting
human, animal, and environmental settings (Aslam
et al. 2018), with estimates pointing to 7M yearly
deaths from infections caused by resistant pathogens
(IACG 2019).
Behavioural and social-economic factors, including
antibiotic over consumption, lack of precise drug usage,
poor sanitation and hygiene practices, access to coun-
terfeit drugs, and increased international transportation,
have helped AMR to spread (Laxminarayan and
Heymann 2012; Ferri et al. 2017; CDC 2019; EFSA 2019).
In healthcare settings, the burden of AMR is substantial,
with high antibiotic intake, patient vulnerability, com-
mon use of invasive practices, and enduring influx of
pathogens being the root causes (Golkar et al. 2014;
Roca et al. 2015). The emergence of multiple resistance
mechanisms has seriously thwarted efforts to achieve
therapeutic success. Clearly, resistant microorganisms
have been and will continue to be a common cause of
treatment failure. The challenge is greatest for critically
ill and immunocompromised patients, though the rising
AMR puts everyone at risk. If no urgent actions are
taken, AMR will cause an estimated 10M deaths by
2050 (IACG 2016).
Clarifying terminologies: resistance,
heteroresistance, tolerance, and persistence
The complexity behind the mechanisms by which
microorganisms evade antimicrobials has led to the cre-
ation of several terminologies and definitions that mul-
tiplied and evolved as new information was outputted.
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Given the ever-growing intricacy of this subject, defini-
tions are often overlapping, making it hard to distin-
guish certain concepts and causing unfortunate
misinterpretations. It is crucial that these definitions are
clear, so researchers can rely on what is published to
advance antimicrobial research. Table 1 summarizes key
differential aspects of the concepts of resistance, heter-
oresistance (HR), tolerance, and persistence, which are
further explored next.
Resistance
Resistance can be classified as intrinsic, acquired, or
adaptive, being usually present concurrently in more
than one of these formats in a given microorganism.
Intrinsic resistance is the innate ability of a microorgan-
ism to resist an antimicrobial because of inherent struc-
tural or functional traits coded in their genome (Blair
et al. 2015). Examples include cell-wall composition
(e.g. Gram-negative vs Gram-positive bacteria), outer
membrane permeability (e.g. restrictive protein chan-
nels), drug efflux pumps (e.g. MexAB-OprM system in
Pseudomonas aeruginosa), and expression of intrinsic
antibiotic resistance genes (e.g. b-lactamases) (Jorge
et al. 2019).
In turn, acquired resistance illustrates the transform-
ation of an originally sensitive microorganism into a
resistant one. This can arise through the acquisition and
incorporation of new genes (carried in plasmids, trans-
posons, integrons, or prophages) from neighbouring
microorganisms by horizontal gene transfer (e.g. spread
of b-lactam resistance among different species).
However, it can also be a result of genetic mutations
(e.g. loss of OprD porin via mutation in the oprD gene
in P. aeruginosa) (Taylor et al. 2014; Pang et al. 2019).
Both intrinsic and acquired resistances are stable and
can be transmitted vertically (Blair et al. 2015).
Adaptive resistance is a more complex form of resist-
ance. Here, microorganisms alter their gene/protein
expression in response to an antimicrobial or environ-
mental factor (e.g. pH, temperature, nutrient or oxygen
concentration) (Jorge et al. 2019). Contrary to intrinsic
and acquired resistances, adaptive resistance is typically
described as unstable, transient, and dependent on the
presence of the triggering factor. The high survival rate
and its temporary nature indicates a non-genetic caus-
ation, making it not vertically transmittable (Sandoval-
Motta and Aldana 2016). Microorganisms revert to their
susceptible state (although sometimes not entirely)
after antibiotic exposure is ceased (Arzanlou et al. 2017;
Pang et al. 2019). This type of resistance is intricate and
not restricted to its more common description. In fact,
adaptive resistance is mechanistically diversified and
sometimes overlaps with other types of resistance.
Mechanisms of adaptive resistance can include epigen-
etic inheritance, heterogeneity of gene expression, high
mutability, population heterogeneity, gene amplifica-
tion, efflux pumps, and biofilm formation (Jorge et al.
2019). For example, some antibiotics can induce a
hypermutator state due to the activation of the SOS
response. Most of these mutations are not stable due
to fitness costs, even though some may confer
Table 1. Overview of resistance, HR, tolerance, persistence definitions.
Concept Characteristics
Transmitted
vertically? Growth? Detection methods
Resistance
Intrinsic  Encoded in genome
 Innate properties
Yes Yes MIC
Acquired  Resistance genes acquired from other microorganisms
(horizontal transfer) or stable mutations
Adaptive  Dependent on triggering factor
 Temporary (mostly) until triggering factor is cut-off
No (mostly)
HR  Subpopulation(s)
 Polyclonal HR: mixed populations or rare resistant
mutants (acquired resistance)
 Monoclonal HR: pure clones; can be stable or unstable




Tolerance  Survival to transient exposure
 Time-dependent (takes longer for antibiotic to kill cells)
 Same MIC as susceptible cells
 Tolerance by slow-growth: inherited non-inherited
Tolerance by lag
Yes (if inherited) Yes Time-kill curve
MDK
Persistence  Subpopulation
 Metabolically inactive cells
 Same MIC as susceptible cells
 Time-dependent persistence: subpopulation of
tolerant bacteria
 Dose-dependent persistence: transient decrease in
antibiotic sensitivity
No No Time-kill curve
HR: Heteroresistance; MBC: minimum bactericidal concentration; MDK: minimum duration for killing; MIC: minimum inhibitory concentration; PAP: popula-
tion analysis profile.
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resistance. However, if the antibiotic stimulus endures,
there is an increased probability of a stable mutation
that confers resistance to occur. This is an example of
how the concepts of acquired and adaptive resistance
may overlap. Adaptive resistance can also be a bridge
between acquired and intrinsic resistance, since genetic
mutations or epigenetic changes caused by environ-
mental signals can alter the expression of intrinsic
resistance mechanisms (Sandoval-Motta and Aldana
2016). Another example of overlapping concepts is
given by the important role of porins and efflux sys-
tems. These typical traits of intrinsic resistance play a
crucial role in adaptive resistance, since antibiotics can
induce the latter by causing an overexpression of those
traits (Fernandez and Hancock 2012).
Heteroresistance
HR is broadly defined by the presence of one or more
microbial subpopulations with higher levels of resistance
then the remaining population. In other words, it
describes heterogeneous microbial populations, wherein
a subset of cells exhibits lower susceptibility to an anti-
microbial (Saravolatz et al. 2014). Several factors need to
be considered when characterising this phenomenon.
HR may be polyclonal or monoclonal. Polyclonal HR is
related to heterogeneous consortia with genetically dis-
tinct subpopulations or to the appearance of rare resist-
ant mutants whose frequency increases with antibiotic
exposure. In turn, HR is monoclonal if present in pure
clones (Andersson et al. 2019). Most published studies
report or study monoclonal HR caused by genetic or
phenotypic heterogeneity (Dewachter et al. 2019).
Depending on the mechanism behind it, HR can be
stable, i.e. the resistance of the subpopulation does not
revert after antibiotic removal, or unstable, i.e. the sub-
population resistance decreases or reverts to suscep-
tible upon antibiotic removal. The level of resistance
(explored further below) and the frequency of the
resistant subpopulation are two other factors to con-
sider when characterising HR (Andersson et al. 2019).
Noteworthy, the frequency of HR relies upon several
variables, including clinical strains involved, antimicro-
bial agent, detection method, and the criterion used to
define it (Nicoloff et al. 2019). To better understand the
factors used to fully characterize HR, the review from
Dewachter et al. (2019) is recommended.
Tolerance
Tolerance is the capacity of a microbial population to
survive a transient exposure to an antimicrobial, even
in concentrations above the minimum inhibitory con-
centration (MIC). Unlike resistance, tolerance is tempor-
ary, since it just takes more time to kill the cells. There
are two types of tolerance, namely tolerance due to
slow growth and tolerance due to lag. Tolerance by
slow growth can be further divided into inherent, i.e.
characteristic of a given species/strain (e.g. long dupli-
cation time), and non-inherent, i.e. caused by poor
growth conditions (e.g. biofilms), stress factors (e.g.
antibiotics), or microbial stationary growth phase. In
turn, tolerance by lag occurs when an antimicrobial is
applied to a microbial population in their lag growth
phase (Brauner et al. 2016; Balaban et al. 2019; Jorge
et al. 2019). Since tolerant and susceptible cells can
exhibit the same MIC, the recommended method to
identify tolerance is time-kill monitoring with assess-
ment of the minimum duration for killing (MDK). It is
also important to refer the concept of dormancy, which
can be viewed as an extreme case of tolerance by slow
growth, i.e. growth rate equal to zero (Brauner
et al. 2016).
Persistence
Persistence, similarly to HR, is characterized by popula-
tion heterogeneity. A major differential aspect between
both phenomena is that while heteroresistant cells
grow during antimicrobial treatment, persisters do not,
given their inactive metabolism (Dewachter et al. 2019;
Jorge et al. 2019). The pattern of antimicrobial sensitiv-
ity in persisters remains identical to that of the main
population (Gefen and Balaban 2009). Persisters consist
of a phenotypic unstable variant, comprising about 1%
of the total population. Persistence can be time- or
dose-dependent. Time-dependent persisters are toler-
ant cells, so everything abovementioned about toler-
ance applies. In turn, dose-dependent persisters have a
transiently overexpression of a resistant factor that
makes them less susceptible, being necessary to apply
higher antimicrobial concentrations to kill them
(Brauner et al. 2016; Dewachter et al. 2019).
Prime factors engendering HR divergent
interpretations
As stated, HR denotes, in its broadest sense, popula-
tion-wide variable responses towards a particular anti-
microbial (El-Halfawy et al. 2013). A formally clear and
consistent accepted definition for HR remains unknown,
owing to contradictable, variable, and confounder fac-
tors, including: i) non-standard criteria (e.g. lack of drug
concentration ranges or cut-off concentrations); ii)
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absence of standardized and accurate diagnostic meth-
odologies; and iii) presence of other forms of
heterogeneity.
The absence of concentration ranges in HR definition
renders it sketchy and may exclude cases of subpopula-
tions with various resistance levels integrated in a sensi-
tive or resistant population (Li et al. 2006; Falagas et al.
2008). In other words, the original culture can be: i) sen-
sitive to an antimicrobial, harbouring a less sensitive
subset of cells that respond to concentrations below
the breakpoint; ii) resistant, but comprising a minor
subpopulation with higher resistance level; or iii)
majorly sensitive, incorporating a small fraction of cells
that are drug resistant (El-Halfawy and Valvano 2015).
The latter case is the classic and most commonly
reported form of HR. It is less likely to be detected by
traditional susceptibility testing, posing serious threats
to antimicrobial treatment due to the selection of the
resistant subpopulations by inappropriate drug dosage
(Li et al. 2017). Thus, specifying the concentration inter-
vals for which a subpopulation is considered resistant
would allow to recognize the various HR levels and
identify the form of HR present (Li et al. 2006; Halaby
et al. 2016).
Oftentimes, rather than include the actual quantified
resistance levels of the population and subpopulation,
HR is only described as fold increases in the MIC of the
main population. Here, the single clinical breakpoints,
obtained from traditional in vitro susceptibility testing
defined by official bodies (e.g. CLSI, CLSI 2016; EUCAST,
Matuschek et al. 2014), are used as cut-off values to dis-
tinguish between homogeneous and heterogeneous
populations. Note that, depending on the method, cut-
off concentrations (Sader et al. 2009; Hermes et al.
2013) or cut-off diameters can be adopted (Khan et al.
2008). To avoid inconsistent HR readings, a definition
was proposed stating that the presence of a
“subpopulation of cells capable of growing under con-
centrations of the antimicrobial drug, at least, eightfold
higher than the highest non-inhibitory concentration of
the dominant population” indicates HR (El-Halfawy
et al. 2013). Other researchers opt to consider all the
microbial colonies falling into zone diameters of 10mm
in disc diffusion assays as heteroresistant (Hallander
and Laurell 1972).
Another factor leading to changeable HR definitions
is the lack of standardized protocols and/or detection
limits of the methodologies used to identify HR (El-
Halfawy and Valvano 2015). The current “gold” standard
test is the population analysis profile (PAP), consisting
of estimating cell counts growing in increasing concen-
trations of the antimicrobial (Søgaard 1985; Søgaard
and Gahrn-Hansen 1986; El-Halfawy et al. 2013).
Although reliable and reproducible, this method is
labour-intensive, time-consuming (3–5 days), and costly,
being cumbersome to implement (Satola et al. 2011;
Van Hal et al. 2011). PAP is usually accomplished with
twofold increments in antimicrobial concentration to
evaluate bacterial growth on agar plates. Nevertheless,
HR frequency, i.e. fraction of the resistant subpopula-
tion growing under antibiotic pressure, varies with the
antimicrobial dose used, precluding comparison
between studies measuring frequencies at different
drug intervals. To make comparisons possible,
Andersson et al. (2019) suggests reporting these fre-
quencies at concentrations eightfold above the resist-
ance level of the main population.
In vitro susceptibility tests routinely used to identify
HR include broth microdilutions, disc diffusions, and E-
tests (Andersson et al. 2019). These methods are faster
and less expensive than PAP, but entail some pitfalls. In
broth microdilution assays, the “skip wells” phenom-
enon (isolated wells exhibiting growth in higher con-
centrations) (Landman et al. 2013; Guerin et al. 2016)
contributes to uninterpretable and irreproducible MIC
results. In turn, agar methods, such as disc diffusion
and E-tests, have limited sensitivity. HR goes mostly
unnoticed in routine antibiograms, as the fraction of
the resistant subpopulation is extremely low (Lo-Ten-
Foe et al. 2007). To allow time for proliferation of less
abundant but more resistant population members,
some researchers suggested prolonging the incubation
time (48 h) and inspecting HR at later time points (Li
et al. 2006; Pournaras et al. 2010; Band et al. 2018).
However, care should be taken when microtiter plates
are incubated for long periods. Long incubations
increase the risk of contamination of the susceptible
population and the likelihood of de novo mutants to
arise, resulting in an inaccurate HR identification.
Additional methods (automated systems and molecular
detection assays) with potential to diagnose HR have
evolved in the last years (e.g. VITEK 2, MicroScan,
WalkAway, GenoType MTBDRplus) (Andersson et al.
2019). Despite, this does not displace the demand of a
practical (i.e. accurate, rapid, sensitive, and cost-effect-
ive) and reliable detection method for routine use in
clinical settings.
Finally, the presence of other forms of heteroge-
neous behaviour in microbial populations may instigate
confusion, generating false HR positives. This can be
discerned, for instance, when a microbial population
exhibits bimodal growth in PAP curves (Kondo et al.
2001). This “Eagle effect” (Eagle and Musselman 1948;
Jarrad et al. 2018) describes a paradoxical “more-kills-
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less” response, wherein a microorganism displays
improved survival when exposed to supra-minimum
bactericidal concentration (MBC) concentrations.
Extensive reports have showed this effect in a wide
range of microorganisms (Lorian et al. 1979;
Fleischhacker et al. 2008; McKay et al. 2009; Wu et al.
2015), though the mechanism behind it remains
unclear.
HR reported in clinically significant pathogens
Healthcare-associated infections (HAIs) remain a major
worldwide concern, contributing to prolonged hospital
stay, patient disability, and economic burden (Khan
et al. 2015, 2017). Several microorganisms, including P.
aeruginosa, Staphylococcus aureus, Burkholderia spp.,
Acinetobacter baumannii, and K. pneumoniae, possess
the ability to endure in medical devices (e.g. urinary
catheters, endotracheal tubes, feeding tubes, vascular
lines) (Safdar and Maki 2002). Because of their oppor-
tunism, these bacteria have been implicated in severe
nosocomial outbreaks (e.g. bloodstream infections,
pneumonia, urinary tract infections, endocarditis). They
can trigger chronic or recurrent life-threatening infec-
tions in critically ill and immunosuppressed patients,
causing high mortality and morbidity rates (Davies and
Davies 2010). The selective pressure provided by the
continuous antibiotic exposure is a key risk factor for
AMR and even for multidrug resistance (MDR) develop-
ment. Worryingly, the majority of the aforementioned
bacteria are priority targets, according to the World
Health Organisation (WHO), stressing the need for new
antibiotics effective against multidrug and extensively
drug resistant pathogens (WHO 2017).
Despite underappreciated, fungal infections also
have unequivocally clinical significance and substantial
burden in healthcare systems. The widespread anti-
biotic misuse coupled with indwelling devices provides
an optimal environment for opportunistic co-coloniza-
tion and proliferation of fungal species (Ganguly and
Mitchell 2011; Weiner et al. 2016; Kean et al. 2018).
Amongst fungi regarded as human pathogens, the
members of the genus Candida are the most frequent.
Candida albicans has long been the prevailing species
co-isolated from polymicrobial infections, interacting
with bacteria and playing key roles in bacterial-fungal
illnesses (Nseir et al. 2007; McCormack et al. 2015;
Townsend et al. 2016; Lopes, Rodrigues, et al. 2017). In
the last decades, however, the emergence of infections
due to other Candida species, such as C. glabrata, C.
parapsilosis, C. tropicalis, and C. krusei, has increased
significantly (Manzano-Gayosso et al. 2008; Negri et al.
2012; Silva et al. 2012).
Despite HR being first reported more than 50 years
ago (Alexander and Leidy 1947; Sutherland and
Rolinson 1964; Kayser et al. 1970), the truth is that HR
prevalence has been disregarded from clinical studies,
likely due to its poor understanding. However, we have
witnessed researchers taking growing interest on this
topic, especially over the last two decades (Figure 1).
HR is becoming a widely accepted problem in health-
care settings, with incidences arising worldwide.
Following up on a preceding report reviewing HR inci-
dences in important bacterial pathogens (El-Halfawy
and Valvano 2015), we hereby gathered the most
recent HR occurrences from the last 5 years
(2015–2020). Table 2 summarizes HR incidences in clin-
ically relevant pathogens, including bacteria and fungi,
to varied antimicrobial categories. Excluding
Burkholderia spp., for which no new HR cases were
found, HR episodes have hugely increased worldwide,
likely resulting from the increasing conscientiousness
regarding the clinical meaningful of this phenomenon.
A summary of the findings is described next.
Acinetobacter baumannii
Carbapenems are the first choice to treat MDR A. bau-
mannii infections, but resistance towards them has
been emerging worldwide (Higgins et al. 2010).
Concerning HR to carbapenems in A. baumannii, one
study reported the selection of imipenem-heteroresist-
ant subpopulations supposedly induced by previous
antibiotic pressure (Li et al. 2017). A complete genome
sequencing analysis identified a small number of inser-
tion sequences in the heteroresistant strain as well as
many mobile genetic elements, however more closely
associated to standard resistant than to heteroresistant
phenotypes. Hence, the HR mechanisms were not
entirely clear in this study.
There has also been an alarming emergence of HR in
A. baumannii to colistin, a last-resort drug. Regrettably,
the underlying mechanisms are also not yet fully under-
stood. Although not fully elucidated the primary mode
of action of colistin, the lipid A in the LPS of the outer
membrane has been recognized as its main target in
Gram-negative bacteria (Formosa et al. 2015). Colistin
acts by displacing the lipopolysaccharide (LPS) content
and solubilising the outer bacterial membrane (Murray
and Hospenthal 2005). The active role of both PmrAB
and PhoPQ systems in regulating colistin HR has been
disclosed, thus leading to membrane/cell wall driven
phenotypes. In the case of A. baumannii, mutations in
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genes linked to the PmrAB regulatory system (pmrA/B
lpxA/D/C), implicated in modifying lipid A biosynthesis
and downregulating the LPS core lipid A regions
(Zhang et al. 2017; Charretier et al. 2018; Rodriguez
et al. 2019; Chen et al. 2020), have been detected in
heteroresistant isolates along with upregulated expres-
sion of efflux pump genes (Machado et al. 2018; Chen
et al. 2020). This denotes that A. baumannii may exhibit
both homogeneous resistant and HR phenotypes, while
presenting mutations in the same targets (Machado
et al. 2018). Similarly to what occurs under carbape-
nems therapy, colistin pressure may lead A. baumannii
populations to harbour a small subpopulation of highly
colistin-resistant variants (Li et al. 2006; Moffatt
et al. 2010).
Despite the well-known aminoglycoside resistance
phenotype of A. baumannii, aminoglycoside HR is rare
in this species. Interestingly, a recent report concerning
tobramycin HR in A. baumannii strain AB5075
(Anderson et al. 2018) uncovered distinct two-way
underlying mechanisms (shown to be highly unstable),
revealing a far more complex process than previously
thought. The first mechanism was acquired through
amplification of the aadB gene, a 200-nucleotidyltransfer-
ase carried in the large plasmid p1AB5075, conferring
resistance to tobramycin and to gentamicin. Although
uncertain, the second was a RecA-independent mech-
anism, unlinked from amplifications of the aadB region.
Klebsiella pneumoniae
Regarded as an emerging cause of severe HAIs (e.g.
urinary tract, bloodstream, soft tissues) (Podschun and
Ullmann 1998), carbapenem-resistant K. pneumoniae
(CRKP) remains in the top urgent threats listed by the
WHO (2017). The analysis of several meropenem-heter-
oresistant mutants showed that the major mechanism
is a deficiency in porin gene (ompK36) expression, fol-
lowed by IS1 insertions and no detectable OmpK36 pro-
tein. The high mutation frequencies (105 to104) are
worrisome and sound the alarm on the risk of develop-
ing carbapenem resistance during therapy (Lopez-
Camacho et al. 2019).
Similarly to A. baumannii, a rapid dissemination of
colistin HR has been increasingly reported. Diverse
studies relate multiple overlapping mechanisms driving
for both colistin-heteroresistant and resistant pheno-
types in K. pneumoniae, generally engendered via muta-
tions in the PhoPQ and PmrAB two-component systems
and/or in the regulator gene mgrB (Berglund 2019). A
likely mechanism can be advocated similarly to that
described for many colistin-heteroresistant
Enterobacteriaceae strains (Kang et al. 2019). Their
decreased susceptibility to polymyxins, namely to colis-
tin, has been mainly attributed to the chemical modifi-
cation of the lipid A. This occurs through the
biosynthesis of abnormal cationic amine moieties of 4-
amino-4-deoxy-L-arabinose (l-Ara4N) and/or
Figure 1. Overview of the number of HR reports over the years. Total number of reports listed in PubMed, embracing the key-
word “Heteroresistance” (last data accessed: October 12 2020).






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CRITICAL REVIEWS IN MICROBIOLOGY 173
phosphoethanolamine (pEtN), aiming at reinforcing the
outer membrane, while neutralising the negatively
charged lipid A and reducing colistin binding and cell
leakage/death (Formosa et al. 2015; Kang et al. 2019).
Alongside to alterations in the lipid A moiety (Jayol
et al. 2015; Cheong et al. 2019), other studies have
reported another source of acquired colistin HR in K.
pneumoniae, which occurs through the inactivation of
MgrB. This transmembrane protein functions as a dis-
ruptor of the negative feedback loop of the PhoPQ
two-component system (Halaby et al. 2016; Bardet et al.
2017). This causes the up-regulation of phoP-associated
genes, creating more positively charged LPS and reduc-
ing its affinity to positively charged polymyxins (Baron
et al. 2016; Jeannot et al. 2017).
In addition, colistin HR in K. pneumoniae has also
been linked to mutations in lpxM and yciM (Halaby
et al. 2016) and in CrrAB (Cheng et al. 2016; Cain et al.
2018). Intriguingly, other non-chromosomal determi-
nants, such as capsule-hyperproduction or overexpres-
sion of RND-type efflux pumps have also been
associated to the colistin-heteroresistant phenotype in
K. pneumoniae (Poirel et al. 2017; Ernst et al. 2020).
Colistin HR in K. pneumoniae can sometimes go
unnoticed with resistant subpopulations requiring
extended incubation times (48 h) to grow in broth dilu-
tion assays (sometimes showing incongruent results in
methodologies using solid substrates) (Band et al.
2018). Moreover, the heteroresistant phenotype can be
highly unstable in K. pneumoniae isolates, which is of
great concern, as it causes unexplained in vivo treat-
ment failure (Band and Weiss 2019).
Reported HR to other antimicrobials (e.g. tetracy-
clines) is shown to be mediated by either OqxAB and
MacAB efflux pumps or by unstable tandem gene
amplifications (Nicoloff et al. 2019).
Pseudomonas aeruginosa
P. aeruginosa stands out in a wide variety of life-threat-
ening acute chronic infections in critically ill and
immunocompromised patients (e.g. CF lung infection,
otitis media, burn wounds, urinary tract and gastro-
intestinal infections) (Moradali et al. 2017; Azam and
Khan 2019). The management of its infections has relied
on several antibiotic categories, including aminoglyco-
sides, cephalosporins, fluoroquinolones, penicillin with
b-lactamase inhibitors (e.g. ticarcillin piperacillin in
combination with clavulanic acid or tazobactam),
monobactams, fosfomycin, and polymyxins (Bassetti
et al. 2018). However, the extreme aptitude of P. aerugi-
nosa to exhibit multiple intrinsically chromosome
encoded mechanisms (e.g. efflux pumps, antibiotic-
inactivating enzymes, target alterations, decreased per-
meability) and genetically imported elements (e.g. plas-
mids) carrying resistance has been jeopardising the
effect of these drugs.
HR emergence in P. aeruginosa has become obvious
as a consequence of its exposure to a high number of
drugs. Analogously to A. baumannii and K. pneumoniae,
colistin HR has been reported in this species.
Accordingly, additional l-Ara4N moieties in lipid A pro-
files were demonstrated in P. aeruginosa heteroresistant
isolates, corroborating the fact that mutations in both
PmrAB and PhoPQ two-component regulatory systems
are a common mechanism by which Gram-negative
bacteria gain colistin resistance (Lin et al. 2019).
Furthermore, two new regulatory systems (ParRS and
CprRS), functioning as cationic peptide sensors, were
found to also play a role in mediating HR in P. aerugi-
nosa (Lin et al. 2019).
Besides colistin, HR to b-lactams has also been
reported. Studies confirmed that AmpC and cephalo-
sporinase overexpression or efflux system upregulation
largely contributes to cefepime HR (Hocquet et al. 2006;
Endimiani et al. 2008; Jia et al. 2020). Similarly, HR to
carbapenems (as well as other antimicrobials) in P. aeru-
ginosa involves remarkable levels of intrinsic Mex-Opr
efflux pump systems (Mei et al. 2015; He et al. 2018;
Qin et al. 2018) or truncation of OprD porin (Qin et al.
2018). Finally, mutations in the gyrA and gyrB target
genes were found to play important roles in ciprofloxa-
cin HR, as fluoroquinolones act by inhibiting the intra-
cellular targets DNA gyrase and topoisomerase IV,
inhibiting DNA replication (Feng et al. 2019).
Staphylococcus aureus
S. aureus is widely encountered in hospital and commu-
nity settings, being closely associated with moderate to
severe invasive infections (Liu et al. 2011). Methicillin-
resistant S. aureus (MRSA) has growing as a leading
cause of HAIs, being more likely to cause serious com-
plications, such as blood sepsis, pneumonia, and endo-
carditis (Siddiqui and Koirala 2019).
Vancomycin is still the foremost therapeutic agent
in serious MRSA infections, yet the ascending resist-
ance towards this glycopeptide has made its use ques-
tionable. In fact, MRSA infections with reduced
susceptibility to vancomycin have emerged in recent
years (Table 2). Particularly, the emergence of the het-
eroresistant vancomycin intermediate S. aureus
(hVISA), associated to prolonged bacteraemia, has con-
tributed to higher rates of poor clinical outcomes
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(Sakoulas et al. 2004; Maor et al. 2009; Claeys et al.
2016). The mechanism by which hVISA occurs is still
unknown, partly explaining why the mechanistic basis
of HR is often unstressed in many studies (Table 2).
One proposed mechanism is the selective pressure
from ever-present and longstanding vancomycin
exposure (Khatib et al. 2015; Di Gregorio et al. 2016;
Martirosov et al. 2017). Studies have also described
various pathways involved in glycopeptides HR,
namely cell wall thickening (Cui et al. 2003), slow
growth rate (Basco et al. 2019), and altered peptido-
glycan cross-linking (Di Gregorio et al. 2017). Genes
related to bacterial cell regulation pathways (vraSR,
graSR, saeSR, agr) (Bakthavatchalam et al. 2016, 2018;
Di Gregorio et al. 2016; Kim et al. 2017), as well as the
presence of the mobile genomic island staphylococcal
cassette chromosome (SCCmec) types I and/or II, carry-
ing genes related to methicillin (and other drugs)
resistance (Silveira et al. 2015; Da Costa et al. 2016;
Huang et al. 2016) have been documented.
HR to daptomycin, a cyclic lipopeptide used as
alternative to treat MRSA infections, has been increas-
ingly seen in MRSA isolates. This HR has been linked
to changes in cell wall composition, charge, and fluid-
ity (Capone et al. 2016; Okado et al. 2018), as well as
to mutations in the mprF gene, resulting in increased
lysyl-phosphatidyl glycerol production, and in the
rpoB/C genes, encoding bacterial RNA polymerase
subunits (Chen et al. 2015; Okado et al. 2018), in add-
ition to a number of other gene mutations (Ji
et al. 2020).
Recently, tetracycline HR has also arisen in both
MRSA and methicillin-susceptible S. aureus (Zhang et al.
2018; Bai et al. 2019). The associated mechanisms are
likely related to drug extrusion through bacterial efflux
pumps (Zhang et al. 2018; Bai et al. 2019).
Candida species
HR has also been witnessed in eukaryotic pathogens,
although at extremely rare frequencies. Ben-Ami et al.
(2016) showed that fluconazole HR in C. glabrata was
fundamentally genotypic, derived from high levels of
efflux pumps, but also epigenetic. Azoles, such as flu-
conazole, inhibit the activity of the lanosterol 14-
a-demethylase, enzyme responsible for ergosterol bio-
synthesis, leading to the accumulation of the toxic
sterol 14-a-methyl-3,6-diol and loss of membrane integ-
rity (Vieira and Nascimento 2017). The widespread and
inadequate use of antifungals may explain the ineffi-
cacy of Candida infection treatments.
Antimicrobial specific analysis of HR
Over the last 5 years, HR to a panoply of antimicrobials
has been reported (Figure 2). Glycopeptides rank first
(31.4%) due to accumulating studies reporting hVISA.
b-lactams stand second, with 18.6% of reported HR
cases. Among them, carbapenems (e.g. imipenem,
meropenem) team up with the highest proportion
(15.4%), assuming particular concern in Gram-negative
bacteria. Antimicrobial peptides assume an equal ratio
than that found for carbapenems. Particularly, the dra-
matic escalation in HR cases towards the last-resource
drug colistin has sounded the alarm to rethink new
effective strategies against MDR strains. Finally, amino-
glycoside HR has an estimated proportion of 6.4%,
while other agents, including synthetic tetracyclines
and sulphonamides, follow with an overall ratio of
6.9%. HR to quinolones (ciprofloxacin) (1.6%) and anti-
fungals (fluconazole) (0.5%) is reported less.
It can be discerned from Figure 2 that nearly all the
portraited categories of antimicrobials filling in the biggest
“slices” of reported HR episodes are the ones interfering
with bacterial membrane or cell wall, either by: i) binding
to targets associated to cell membrane/cell wall function
(e.g. glycopeptides; carbapenems); ii) acting as permeabil-
izers, displacing bacterial membrane architecture (e.g.
colistin); or iii) interacting with the anionic cell surface
whilst holding a very positive charge (cationic) at neutral
pH, being known to be affected by membrane modifica-
tion (aminoglycosides) (Krause et al. 2016). On the other
hand, HR to agents targeting other vital cell components
is less reported. Quinolones HR, for instance, derives from
combined forms of resistance, namely target-mediated
resistance (in gyrase and topoisomerase IV) along with cel-
lular efflux pump overexpression and repression of porin
channels (Aldred et al. 2014; Qin et al. 2018).
For a more complete overview, Table 3 summarizes
HR incidences in clinically significant pathogens
towards different antimicrobials, reported over the last
2 decades. There is an upward trend in the number of
new reports, showing a growing interest for this topic,
particularly with the advent of sophisticated diagnostic
technologies. Reporting HR occurrences in pathogens
with clinical importance and elucidating the underlying
mechanisms would significantly enhance our under-
standing of HR implications in AMR development and
its correlation with therapeutic failure, ultimately help-
ing to guide effective therapeutic options.
Biofilm as a form of resistance
Biofilm development is a process whereby microorgan-
isms irreversibly attach and grow on interfaces,
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clumping as well-organized multicellular aggregates or
layers with distinct architectures to persist in a wide
range of environments (Lebeaux et al. 2014; Flemming
and Wuertz 2019). These microorganisms are sheltered
and spatially confined in a self-produced polymeric
matrix, representing a major healthcare concern owing
to their detrimental role in many infections, namely
those associated with medical devices (Lebeaux et al.
2014). Pathogens grow in biofilms as a form of adaptive
resistance and as a versatile strategy to invade the
human body, becoming impervious to host defences
and external stressors, such as antimicrobials (Bisht and
Wakeman 2019). Biofilm-associated infections are not
easily eradicated by conventional treatments, as micro-
organisms living as biofilms are 10- to 1000-fold more
tolerant to antimicrobials than their free-living counter-
parts (Romling et al. 2012; Lopes et al. 2014).
A significant mechanism contributing to the
increased AMR found in biofilms is the restricted drug
penetration through the exopolysaccharide matrix. This
matrix fulfils a variety of functions, ranging from struc-
tural robustness and protection from environmental
stresses to gene regulation and nutrient adsorption
(Hobley et al. 2015). Remarkably, the matrix is proficient
in enmeshing microorganisms into a diffusion-limiting
area, sparking microbial organization into a wide range
of physiological states. Consequently, biofilms become
inherently heterogeneous communities, even when
formed by a single species (Stewart and Franklin 2008).
Biofilm heterogeneity results from a highly complex
interplay between stochastic stressors, such as spontan-
eous mutations, external stimuli factors (e.g. host
immune system, antimicrobial treatment), internal
microenvironment (oxygen, nutrient, and pH gradients),
and interspecies interactions (Lebeaux et al. 2014; Bisht
and Wakeman 2019). Taken together, these processes
lead to the formation of widely distinct subpopulations
within the biofilm strata with diversified metabolic pro-
files, genetic programs, spatial segregation, and differ-
ential stress responses (Hall-Stoodley et al. 2004; Pamp
et al. 2008; Stewart and Franklin 2008; Høiby et al. 2010;
Yan and Bassler 2019). The higher the biofilm biomass,
the more evident this interplay and the larger the num-
ber of emerging subpopulations will be (Bisht and
Wakeman 2019).
However, increased amount of biomass does not
necessarily means increased AMR (Naparstek et al.
2014), but rather increased heterogeneity. Typically, a
top-to-bottom gradient of decreasing susceptibilities
can be found in most biofilms. The selective pressure
Figure 2. HR to different antimicrobials. Number of cases reporting antimicrobial HR, expressed as percentage, reported in clinic-
ally significant pathogens during the last 5-year period annotated in this review.
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provided by the accumulation of intercellular signalling
molecules and waste products, along with oxygen and
nutrient gradients, lead biofilm subpopulations to dis-
play differential growth and metabolic rates, ultimately
antagonising the action of antimicrobials (Borriello
et al. 2004; Stewart and Franklin 2008; Ryall et al. 2012;
Jensen et al. 2017). In P. aeruginosa biofilms, for
instance, metabolic active bacteria are mostly located
in the outer layers, whereas low or non-metabolic
active cells are in the lower regions (Xu et al. 1998;
Walters et al. 2003; Bagge et al. 2004; Borriello et al.
2004; Williamson et al. 2012). In this biofilm arrange-
ment, most antibiotics targeting biological processes
during aerobic respiration (e.g. DNA replication, transla-
tion, cell wall synthesis) are only capable of clearing the
outer layers (Brooun et al. 2000; Walters et al. 2003;
Williamson et al. 2012; Soares et al. 2019). However, bio-
film physiological stratification is not always consistent
among species. In Escherichia coli macrocolonies, the
active growing cells are located in the lower layers,
while non-growing starving bacteria inhabit the upper
ones in response to a diffusion-based nutrient supply
(Serra et al. 2013). Other distinct biofilm stratifications
include the three-layer patterns discerned in S. aureus,
S. epidermidis, and in b-lactamase-negative K. pneumo-
niae microcolonies biofilms (Anderl et al. 2003; Rani
et al. 2007). In the case of S. aureus, bacterial cells pref-
erentially grow aerobically and fermentatively in layers
near to air interfaces, whereas non-growing cells are
sustained in the middle layers (Rani et al. 2007).
Heterogeneity in resistance levels within biofilms can
be exhibited in a growth state-dependent manner. This
form of resistance results from nutritional and oxygen
constraints within the biofilm microenvironments or
from antimicrobial exposure, which drive a small frac-
tion of the population to enter a dormant or slow-
growth state (persisters) (Allison et al. 2011; Conlon
et al. 2015; Hall and Mah 2017; Soares et al. 2019). Once
persisters are capable of surviving to lethal antimicro-
bial concentrations (Conlon et al. 2015; Soares et al.
2019), they are responsible for relapsing many biofilm-
associated infections (Conlon 2014; Gollan et al. 2019).
As such, the physiological heterogeneity in biofilms
causes differential yet concerted resistance and toler-
ance mechanisms (Jorge et al. 2019). Regrettably, the
contribution of biofilm subpopulations and their inher-
ent variability to HR emergence is still poorly explored.
While significant progress has been made in exploiting
worldwide HR incidences, the fact is that the bulk of
research is focused in planktonic microorganisms. So
far, there is only one report addressing HR in biofilms
(Silva et al. 2016), wherein heteroresistant subpopula-
tions with ability to grow under colistin concentrations
up to fourfold the MIC were found in K. pneumoniae
biofilms. The resistant subpopulation exhibited a distin-
guishable colony morphology from the remaining bio-
film population in the form of stable small-colony
variants. These latest findings are reasonable grounds
to anticipate occurrence of HR within biofilms, with the
tremendous heterogeneous physiologies typically
found in biofilms predicting the onset of such
Table 3. Overview of reported antimicrobial HR incidences in clinically significant pathogens.
Pathogen




































Glycopeptides n/a n/a n/a n/a n/a Vancomycin
Teicoplanin
Lipopeptides n/a n/a n/a n/a n/a Daptomycin
Quinolones n/a Norfloxacin n/a n/a Ciprofloxacin n/a







SMX: Sulfamethoxazole; TMP-SMX: Sulfamethoxazole/trimethoprim; n/a: not annotated.
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phenotype. Taking this premise into consideration, we
propose a theoretical model representing the heteroge-
neous physiologies that might arise in biofilms
(Figure 3).
A total of five distinct AMR patterns can arise in poly-
microbial biofilms, comprising: susceptible, resistant,
and tolerant populations; a highly tolerant persister
subpopulation; and a highly resistant subpopulation
(HR subpopulation) (Figure 3(A)). When biofilms are
exposed to antimicrobials, metabolically active suscep-
tible cells, largely located at the top tiers, are promptly
killed, whereas both resistant and heteroresistant cells
are able to replicate under antimicrobial stress.
Persisters, however, remain in a dormant state, not dis-
turbed by the antimicrobials. Tolerant cells are able to
survive antimicrobial action, however taking a longer
time to grow (Figure 3(B)). When antimicrobial pressure
drops, the resistant populations endure with their previ-
ous replicated numbers (in case of adaptive resistance,
cells return to a susceptible profile). Usually, heterore-
sistant subpopulations, if unstable, revert to their ori-
ginal susceptibility patterns (Figure 3(C)). This selection
for resistant, tolerant, and persister cells is a major con-
cern in antibiotherapy and commonly the reason for
infection recalcitrance and chronicity.
Polymicrobial biofilms in chronic infections
The notion that biofilms rarely exist as single-species
entities and that most persistent infections are medi-
ated by complex heterogeneous polymicrobial com-
munities spanning different phylogenetic kingdoms is
now widely recognized (Peters et al. 2012; Filkins and
O’Toole 2015; O’Donnell et al. 2015; Kline and Lewis
2016). The presence of different microorganisms living
in close proximity complicates the clinical picture of
these polymicrobial infections (Lopes et al. 2012; Lopes,
Azevedo, et al. 2017; Stacy et al. 2016). These type of
infections have been reported to cause even worse out-
comes than single-species infections (Pammi et al.
2014; Limoli et al. 2016; Limoli and Hoffman 2019) and
are often associated to higher mortality rates.
Microorganisms interact within the infection niche, aug-
menting the tenacity and recalcitrance of the infection
(Azoulay et al. 2006; Hamet et al. 2012; Wolcott et al.
2013; Schroeder et al. 2017), paving the way for AMR
evolution. These interactions can cause tremendous dis-
turbance in microbial physiology in ways that affect dis-
ease progression outcome, by means of virulence factor
upregulation (Duan et al. 2003; Sibley et al. 2008;
Korgaonkar et al. 2013), altered biofilm formation (Ryan
et al. 2008; Bragonzi et al. 2012; Lopes et al. 2012), and
altered antibiotic susceptibility (Beaudoin et al. 2017;
Lopes, Azevedo, et al. 2017, Lopes, Rodrigues, et al.
2017; Orazi and O’Toole 2017; Orazi et al. 2019).
Indeed, a striking characteristic of most chronic
infections mediated by polymicrobial biofilms is their
unsuccessful eradication by conventional therapy. The
mechanisms that lead to unexplained treatment failures
and poorer clinical outcome remain unclear, with HR as
a likely cause. In addition to suboptimal therapeutic
dosages that ignore the high resistance and tolerance
levels of biofilms, there are other reasons for antibiotic
treatment failure. They are related to the selection of
the resistant cells within biofilms and the dissemination
of resistance traits due to facilitated interactions among
microorganisms (El-Halfawy and Valvano 2011, 2015).
HR within a clonal cell population, despite rarely
reported in biofilms, has been documented for several
opportunistic pathogens with prominent roles in these
infections, dramatically impacting the chronicity of such
illnesses (Fusco et al. 2009; Higgins et al. 2010; Cheong
et al. 2011; Sola et al. 2011; Campanile et al. 2012; El-
Halfawy et al. 2013; Silveira et al. 2015; Band et al. 2016,
2018; Huang et al. 2016). Predictably, highly resistant
cells that make up heteroresistant subpopulations may
further complicate polymicrobial infections by affording
protection to more susceptible cells (from the same or
different species), either by counteracting antimicrobial
effects through the release of neutralising elements or
by means of metabolic (cooperative) interplay and
cell–cell communication via sharing genetic material/
resistance genes (Dufour and Rao 2011). This issue is
discussed next.
Resistance spreading through interspecies
interactions – clinical magnitude and
implications in HR
The emergence of dissimilar levels of resistant pheno-
types in heteroresistant populations has been assumed
to be a reflection of variations in stochastic processes,
in environmental metabolic clues, and of genetic archi-
tecture (circuits) (Norman et al. 2015; Dewachter et al.
2019). HR mechanisms, despite still unclear, presumably
fall into 3 major categories: i) drug target modification;
ii) drug inactivation; and iii) reduction of intracellular
drug concentration (Band et al. 2016; Nicoloff et al.
2019). Also, HR (monoclonal) may have a phenotypic
(i.e. non-genetic) or a genetic basis. Regardless of HR
stability, it can, unfortunately, promote adaptive evolu-
tion. Under drug stress, the development of high rate
cumulative mutations by resistant subpopulations may
result in adaptive benefit to the whole population by
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Figure 3. Heterogeneous physiologies in biofilms. (A) Five distinct patterns of AMR can arise simultaneously in biofilms when a
theoretical minimum of three different species or strains are present: susceptible or metabolically active population (dark solid
bacilus with shadowing); resistant (coccus) tolerant (diplococcus) populations; persister subpopulation, preferentially located at
the bottom layers (light solid bacilus with shadowing); a heteroresistant (patterned bacilus with shadowing) subpopulation (HR).
(B) Under antimicrobial selective pressure, metabolically active cells are killed, both resistant HR populations are able to replicate.
Contrariwise, persisters are not affected by the antimicrobial activity tolerant cells are able to survive however exhibiting slow
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augmenting its resistance or inducing HR in neighbour-
ing cells (Li et al. 2017; Dewachter et al. 2019). Looking
into co-infection scenarios, this review intends to pin-
point mechanisms of microbial resistance communica-
tion to gain insights into the implications that
interspecies interactions may have on HR and on the
outcome of polymicrobial infections.
Genetic mechanisms of resistance spreading
Even though HR stability is generally disregarded, sev-
eral mechanisms have been proposed. Mutations on
resistance genes, through either single-nucleotide poly-
morphisms (SNPs), frameshifts, or insertions/deletions,
generate a stable HR, causing subpopulations to retain
their resistance when antibiotic selective pressure
drops. Unstable HR, on the contrary, is largely linked to
tandem and unstable gene amplifications, although
point mutations, insertion sequences, and small dele-
tions can also occur. These genetic events explain why
HR is highly unstable and transient in nature, frequently
evading routine diagnostic tests (Andersson et al.
2019). In addition, gene modifications are generally
intrinsic, conferring unfavourable effects by occurring
at high rates through a disproportionate crossing over
between homologous amplified gene copies (Adler
et al. 2014; Reams and Roth 2015; Nicoloff et al. 2019).
The resistant subpopulations with amplifications in
regulatory genes (Landman et al. 2013; Jayol et al.
2015; Halaby et al. 2016), resistance genes encoding
efflux systems (Chen et al. 2017; Zheng et al. 2018),
and/or antibiotic/target-modifying or antibiotic-degrad-
ing enzymes (Sandegren and Andersson 2009), are
selected and enriched under drug selective pressure.
Whenever pressure drops, susceptible revertant cells
are forced to reduce the number of gene copies and
decelerate or suppress their growth (Sandegren and
Andersson 2009; McGann et al. 2014; Nicoloff
et al. 2019).
The fact that various genetic transfer mechanisms
contribute extensively to resistance spreading in micro-
bial populations is infamous. The frequency of inherited
and spontaneous mutations and the horizontal
exchange of resistance determinants is facilitated by
high cell densities and their close proximity in polymi-
crobial biofilms (Hausner and Wuertz 1999; Driffield
et al. 2008; Andersson and Hughes 2010; Orazi and
O’Toole 2019). The emergence and dissemination of
antibiotic resistance genes through horizontal gene
transfer and integrative conjugative elements is well
reported in these scenarios, converting biofilms into
AMR hot spots (Li et al. 2018).
Considered a major pathway for spreading resistance
genes, plasmid-mediated conjugation can transfer DNA
between species from different genera and phyla
(Sørensen et al. 2005). Biofilms are well suited for gene
transferability, promoting abnormal rates of conjuga-
tion (Hausner and Wuertz 1999). One example com-
prises the transmission of an E. coli natural NDM-type
plasmid encoding the carbapenemase-associated resist-
ance gene blaNDM-1 to P. aeruginosa and A. baumannii
(Tanner et al. 2017). Another example is the acquisition
of resistance towards vancomycin and other antibiotics,
by S. aureus. This resistance is likely mediated through
plasmid-horizontal transfer during the course of a poly-
microbial biofilm infection. For example, the vanA-har-
bouring plasmid was presumably transferred from
Enterococcus faecium to S. aureus (Weigel et al. 2007).
Interestingly, the occurrence of S. aureus in heteroge-
neous biofilms tends to increase the rates of plasmid
horizontal transfer, contributing to biofilm resistance
(Venkatesan et al. 2015).
Usually, bacteria synthetize enzymes possessing
deleterious effects against certain antibiotics. Within
the various families of antibiotic-inactivating enzymes,
b-lactamases are the most impacting ones. Particularly,
the extended-spectrum b-lactamases (ESBL) are associ-
ated with major outbreaks of cephalosporin-resistant
infections caused by ESBL-producing E. coli and K. pneu-
moniae (Sirot et al. 1988; Meyer et al. 1993). The genes
encoding these enzymes were generally detected in
plasmids that confer resistance to multiple antibiotic
classes and are readily transferable among species
(Sirot et al. 1987). b-lactamases have risen worldwide in
pan-resistant Gram-negative pathogens, and their cod-
ing genes have spread into other Enterobacteriaceae as
well as P. aeruginosa and Acinetobacter spp. (Queenan
Figure 3. (Continued)
growth. (C) When antimicrobial pressure drops, the resistant population maintains its numbers (however, some cells with adap-
tive resistance may revert to susceptible); HR subpopulation reverts to their original susceptibility patterns. Of note, it was
intended to represent all conceivable AMR patterns that can be present at a biofilm. Bearing in mind that resistance tolerance
are reflected in entire populations, we differentiate cell shapes into bacillus, coccus, diplococcus, to represent different species.
Therefore, this model can be representative of a three-species biofilm. It is important to underscore that the top-to-bottom gradi-
ent antibiotic susceptibilities in this model may do not reflect what occurs in several biofilm mixed-species populations (in some
cases, one species may overlay another).
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and Bush 2007; Robledo et al. 2010). These findings
strongly illustrate the potential for dissemination of
resistance determinants between pathogens in the con-
text of polymicrobial infections. Of note, a single conju-
gative event can have extensive implications in AMR
spreading, not only within an infection but also
between patients, having potential repercussions in
antimicrobial treatment (Orazi and O’Toole 2019).
Non-genetic mechanisms of resistance spreading
Non-genetic mechanisms of resistance spreading are
often dismissed, perhaps overshadowed by genetic
machineries, making them not always clear.
Nonetheless, there is increasing evidence showing
modulation of population-wide resistance communica-
tion through non-genetic processes. Epigenetic inherit-
ance is an example of non-genetic HR, and partially
explains the vertical transmission of HR across genera-
tions without ensuring its stability (Dewachter et al.
2019). Another example involves the production and
release of chromosomal- or plasmid-encoded enzymes
(e.g. b-lactamases), particularly by Gram-negative bac-
teria, providing protection not only for the producer
but also for neighbouring cells (Lee et al. 2013; Perez
et al. 2014; Sorg et al. 2016; Kim et al. 2018). In biofilms,
these enzymes assume particular importance as they
accumulate within the matrix, degrading the antibiotic
before it can reach the cells (Bush 2010; Høiby
et al. 2010).
Microorganisms also possess signal transduction
machineries called quorum-sensing (QS) that rely on
chemical signals, enabling cell–cell communication and
multicellular behaviour regulation. QS is required by
prokaryotes and eukaryotes to coordinately respond to
environmental stressors through the expression of
genes mediating virulence and resistance traits
(Abisado et al. 2018). Interspecies communication
through QS signals impacts antibiotic sensitivity within
polymicrobial biofilms, with one species offering pro-
tection to another. For example, S. aureus and P. aerugi-
nosa develop intricate regulatory networks not only to
evade and suppress each other (Hotterbeekx et al.
2017), but also to establish cooperative ecological rela-
tionships (Magalh~aes et al. 2019). HQNO (2-heptyl-4-
hydroxyquinolone N-oxide), a molecule pertaining to
the Pseudomonas quinolone signal (PQS) QS system
pathway, shields S. aureus from multiple antibiotics
(Hoffman et al. 2006; Orazi and O’Toole 2017). P. aerugi-
nosa drives S. aureus towards fermentative metabolism
and reduced ATP levels, resulting in staphylococcal
reduced antibiotic sensitivity (Filkins et al. 2015;
Radlinski et al. 2017). QS signals and related diffusible
molecules can also impact antimicrobial efficacy by
altering cell membranes. S. maltophilia provides P. aeru-
ginosa resistance to polymyxins through signal factors
that are perceived by P. aeruginosa, which responds by
activating the two-component system PmrAB (Ryan
et al. 2008).
Cross-kingdom interactions in polymicrobial infec-
tions may also enhance resistance and virulence mech-
anisms. For example, C. albicans protects S. aureus by
synthetising the QS molecule farnesol, which
decreases the susceptibility of S. aureus to vanco-
mycin. Farnesol induces the production of reactive
oxygen species in S. aureus, activating a general stress
response, and upregulates bacterial efflux pumps
(Kong et al. 2017). Another example is the dual-species
biofilms encompassing C. albicans and P. aeruginosa
that exhibits abnormal resistance towards antifunga-
l–antibacterial (amphotericin B-polymyxin B) combina-
torial therapy. Even though the mechanisms have not
been fully elucidated, the authors proposed a mechan-
ism whereby protection of one species to another con-
fers augmented overall resistance (Lopes, Rodrigues,
et al. 2017).
Several metabolites (e.g. indole, ammonia, nitric
oxide, polyamines), secreted by bacteria or by host
cells, act as cell signals and have been reported to influ-
ence biofilm formation and antimicrobial efficacy
(Gusarov et al. 2009; Nijland and Burgess 2010; Lee and
Lee 2010; El-Halfawy and Valvano 2012; Bernier and
Surette 2013; El-Halfawy et al. 2013; Arora et al. 2015).
For instance, indole, an aromatic compound produced
by a vast number of bacteria (Lee and Lee 2010), can
be sensed in a heterogeneous manner across different
species. For example, indole is known to stimulate P.
aeruginosa biofilm formation and, despite repressing
QS-regulated virulence factors (e.g. pyocyanin, rhamno-
lipid, PQS, pyoverdine), to induce resistance to tetracyc-
line, gentamicin, and ampicillin (Lee et al. 2009). Indole
also protects persisters against oxidative stress (Vega
et al. 2012).
Volatile compounds, such as ammonia, 2,3-butane-
dione, and polyamines, also constitute a large class of
potential infochemicals with ability to shift antimicro-
bial susceptibility profiles within microbial communities
(Kai et al. 2009; El-Halfawy et al. 2013). Volatile-medi-
ated communication is particularly troublesome in that
no intimate cell–cell contact is required. Exposure to
biogenic ammonia, for instance, resulted in increased
resistance to tetracycline in various Gram-negative and
Gram-positive bacteria, including P. aeruginosa and S.
aureus (Bernier et al. 2011). Polyamines, synthesized by
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nearly all bacteria (Tabor and Tabor 1984), play import-
ant functions by regulating bacterial growth, biofilm
formation, biosynthesis of siderophores, cellular differ-
entiation, and AMR (Wortham et al. 2007; Kohanski
et al. 2010; Johnson et al. 2012; Tkachenko et al. 2012).
Given their ubiquitous occurrence in bacteria, their
accumulation in the environmental milieu is antici-
pated. At infection sites, polyamines tissue levels
increase significantly, contributing to interspecies com-
munication in multiple ways (Zhang et al. 2000;
Bjelakovic et al. 2010). A great example demonstrating
polyamines as great HR and resistance-spreading medi-
ators across distinct bacterial populations was observed
with putrescein. Secreted at abundant levels by a highly
resistant subpopulation of Burkholderia cenocepacia,
this polyamine provided antimicrobial protection to
sensitive P. aeruginosa. This interaction relied on the
synthesis of putrescein by the resistant subpopulation,
acting in concert with the Burkholderia conserved pro-
tein Ycel, to afford protection to the outer membrane
of P. aeruginosa from polymyxin B attack (El-Halfawy
et al. 2013).
Overall, these mechanisms partly account for the
increased recalcitrance observed in polymicrobial bio-
film-mediated infections. Furthermore, their disclosure
may help decipher the role of these consortia as a
“gold” opportunity for interspecies commutation of
resistance determinants in heteroresistant populations,
thus elevating its magnitude in endangering antimicro-
bial therapies of these infections.
Concluding remarks
It has been widely recognized that biofilms display high
levels of heterogeneity at infection sites, consequently
generating subsets of phenotypes specialized at surviv-
ing antimicrobial attacks. Here, we focussed on HR, a
yet poorly understood phenomenon, in which only a
subset of cells in a population is resistant to antimicro-
bial treatment. The continuous HR emergence in clinic-
ally relevant pathogens is alarming and might be a
significant cause of therapeutic failure in chronic and
recurrent infections, which are often polymicrobial. HR
incidence in biofilms is still largely underestimated.
Moving forward, we argue that this phenomenon
should no longer be ignored, being of utmost import-
ance that we thoroughly investigate all aspects of HR.
To increase the chance of detecting HR, we suggest
revising the criteria for HR identification in consortia,
either through using clinically meaningful biofilm sus-
ceptibility endpoint parameters (e.g. extending cut-off
values to minimum biofilm inhibitory concentrations
rather than MIC), extending the biofilm incubation time
(as HR has a prolonged lag phase comparatively to
native populations), or both. To accomplish this, more
accurate and sensitive diagnostic tools are needed for
major advances. Only after having a comprehensible
understanding of the molecular mechanisms underpin-
ning HR, we will be allowed to discern how we might
overcome them. Future research is also required to elu-
cidate the molecular basis of HR communication and its
role in resistance spreading. Only then we will be able
to find strategies to counteract HR, through effective
inhibitors of key cooperation pathways. This will hope-
fully also translate into a more uniform response to bio-
film infection treatment and a reduction in therapeutic
failure. At this moment, HR is still an emerging field in
need of clarity.
Disclosure statement
The authors declare no potential conflict of interest.
Funding
This work was supported by the Portuguese Foundation for
Science Technology (FCT) under the scope of the strategic
funding of UID/BIO/04469/2020 unit BioTecNorte operation
[NORTE-01-0145-FEDER-000004] funded by the European
Regional Development Fund under the scope of
Norte2020–Programa Operacional Regional do Norte. The
authors also acknowledge COMPETE2020 FCT for the project
POCI-01-0145-FEDER-029,841 and for the Scientific
Employment Stimulus 2017 grant [CEECIND/01507/2017] (A.
M. Sousa).
ORCID
Susana Patrıcia Lopes http://orcid.org/0000-0002-
8183-1695
Paula Jorge http://orcid.org/0000-0001-7860-4179
Ana Margarida Sousa http://orcid.org/0000-0002-
8900-2656
Maria Olıvia Pereira http://orcid.org/0000-0002-4307-3985
References
Abisado RG, Benomar S, Klaus JR, Dandekar AA, Chandler JR.
2018. Bacterial quorum sensing and microbial community
interactions. mBio. 9:e02331-17.
Adler M, Anjum M, Berg OG, Andersson DI, Sandegren L.
2014. High fitness costs and instability of gene duplica-
tions reduce rates of evolution of new genes by duplica-
tion-divergence mechanisms. Mol Biol Evol. 31:1526–1535.
Aldred KJ, Kerns RJ, Osheroff N. 2014. Mechanism of quin-
olone action and resistance. Biochemistry. 53:1565–1574.
182 S. P. LOPES ET AL.
Alexander HE, Leidy G. 1947. Mode of action of streptomycin
on type B Hemophilus influenzae : II. Nature of resistant
variants. J Exp Med. 85:607–621.
Allison KR, Brynildsen MP, Collins JJ. 2011. Heterogeneous
bacterial persisters and engineering approaches to elimin-
ate them. Curr Opin Microbiol. 14:593–598.
Anderl JN, Zahller J, Roe F, Stewart PS. 2003. Role of nutrient
limitation and stationary-phase existence in Klebsiella
pneumoniae biofilm resistance to ampicillin and ciprofloxa-
cin. Antimicrob Agents Chemother. 47:1251–1256.
Anderson SE, Sherman EX, Weiss DS, Rather PN. 2018.
Aminoglycoside Heteroresistance in Acinetobacter bauman-
nii AB5075. mSphere. 3:e00271–18.
Andersson DI, Hughes D. 2010. Antibiotic resistance and its
cost: is it possible to reverse resistance? Nat Rev Microbiol.
8:260–271.
Andersson DI, Nicoloff H, Hjort K. 2019. Mechanisms and clin-
ical relevance of bacterial heteroresistance. Nat Rev
Microbiol. 17:479–496.
Arora DP, Hossain S, Xu Y, Boon EM. 2015. Nitric oxide regu-
lation of bacterial biofilms. Biochemistry. 54:3717–3728.
Arzanlou M, Chai WC, Venter H. 2017. Intrinsic, adaptive and
acquired antimicrobial resistance in Gram-negative bac-
teria. Essays Biochem. 61:49–59.
Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S,
Rasool MH, Nisar MA, Alvi RF, Aslam MA, Qamar MU, et al.
2018. Antibiotic resistance: a rundown of a global crisis.
Infect Drug Resist. 11:1645–1658.
Azam MW, Khan AU. 2019. Updates on the pathogenicity sta-
tus of Pseudomonas aeruginosa. Drug Discov Today. 24:
350–359.
Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M,
Zahar JR, Adrie C, Garrouste-Orgeas M, Cohen Y,
Mourvillier B, et al., Outcomerea Study Group. 2006.
Candida colonization of the respiratory tract and subse-
quent Pseudomonas ventilator-associated pneumonia.
Chest. 129:110–117.
Bagge N, Hentzer M, Andersen JB, Ciofu O, Givskov M, Høiby
N. 2004. Dynamics and spatial distribution of beta-lacta-
mase expression in Pseudomonas aeruginosa biofilms.
Antimicrob Agents Chemother. 48:1168–1174.
Bai B, Lin Z, Pu Z, Xu G, Zhang F, Chen Z, Sun X, Zheng J, Li
P, Deng Q, et al. 2019. In vitro activity and heteroresist-
ance of omadacycline against clinical Staphylococcus aur-
eus isolates from China reveal the impact of omadacycline
susceptibility by branched-chain amino acid transport sys-
tem II carrier protein, Na/Pi cotransporter family protein,
and fibronectin-binding protein. Front Microbiol. 10:2546.
Bakthavatchalam YD, Ramaswamy B, Janakiraman R, Steve
RJ, Veeraraghavan B. 2018. Genomic insights of commu-
nity-acquired methicillin-resistant Staphylococcus aureus
(MRSA) with reduced teicoplanin susceptibility: a case of
fatal necrotizing fasciitis. J Glob Antimicrob Resist. 14:
242–245.
Bakthavatchalam YD, Veeraraghavan B, Peter JV, Rajinikanth
J, Inbanathan FY, Devanga Ragupathi NK, Rajamani Sekar
SK. 2016. Novel observations in 11 heteroresistant vanco-
mycin-intermediate methicillin-resistant Staphylococcus
aureus strains from South India. Genome Announc. 4:
e01425–16.
Balaban NQ, Helaine S, Lewis K, Ackermann M, Aldridge B,
Andersson DI, Brynildsen MP, Bumann D, Camilli A, Collins
JJ, et al. 2019. Definitions and guidelines for research on
antibiotic persistence. Nat Rev Microbiol. 17:441–448.
Band VI, Crispell EK, Napier BA, Herrera CM, Tharp GK,
Vavikolanu K, Pohl J, Read TD, Bosinger SE, Trent MS, et al.
2016. Antibiotic failure mediated by a resistant subpopula-
tion in Enterobacter cloacae. Nat Microbiol. 1:16053.
Band VI, Satola SW, Burd EM, Farley MM, Jacob JT, Weiss DS.
2018. Carbapenem-resistant Klebsiella pneumoniae exhibit-
ing clinically undetected colistin heteroresistance leads to
treatment failure in a murine model of infection. mBio. 9:
e02448–17.
Band VI, Weiss DS. 2019. Heteroresistance: a cause of unex-
plained antibiotic treatment failure? PLoS Pathog. 15:
e1007726.
Bardet L, Baron S, Leangapichart T, Okdah L, Diene SM,
Rolain JM. 2017. Deciphering heteroresistance to colistin
in a Klebsiella pneumoniae isolate from Marseille, France.
Antimicrob Agents Chemother. 61:e00356–17.
Baron S, Hadjadj L, Rolain JM, Olaitan AO. 2016. Molecular
mechanisms of polymyxin resistance: knowns and
unknowns. Int J Antimicrob Agents. 48:583–591.
Basco MDS, Kothari A, McKinzie PB, Revollo JR, Agnihothram
S, Azevedo MP, Saccente M, Hart ME. 2019. Reduced
vancomycin susceptibility and increased macrophage sur-
vival in Staphylococcus aureus strains sequentially isolated
from a bacteraemic patient during a short course of anti-
biotic therapy. J Med Microbiol. 68:848–859.
Bassetti M, Vena A, Croxatto A, Righi E, Guery B. 2018. How
to manage Pseudomonas aeruginosa infections. Drugs
Context. 7:212527.
Beaudoin T, Yau YCW, Stapleton PJ, Gong Y, Wang PW,
Guttman DS, Waters V. 2017. Staphylococcus aureus inter-
action with Pseudomonas aeruginosa biofilm enhances
tobramycin resistance. NPJ Biofilms Microbiomes. 3:25.
Ben-Ami R, Zimmerman O, Finn T, Amit S, Novikov A,
Wertheimer N, Lurie-Weinberger M, Berman J. 2016.
Heteroresistance to fluconazole is a continuously distrib-
uted phenotype among Candida glabrata clinical strains
associated with in vivo persistence. mBio. 7:1–12.
Berglund B. 2019. Acquired resistance to colistin via chromo-
somal and plasmid-mediated mechanisms in Klebsiella
pneumoniae. Infectious Microbes Diseases. 1:10–19.
Bernier SP, Surette MG. 2013. Concentration-dependent activ-
ity of antibiotics in natural environments. Front Microbiol.
4:20.
Bernier SP, Letoffe S, Delepierre M, Ghigo JM. 2011. Biogenic
ammonia modifies antibiotic resistance at a distance in
physically separated bacteria. Mol Microbiol. 81:705–716.
Bisht K, Wakeman CA. 2019. Discovery and therapeutic tar-
geting of differentiated biofilm subpopulations. Front
Microbiol. 10:1908.
Bjelakovic G, Stojanovic I, Jevtovic Stoimenov T, Pavlovic D,
Kocic G, Rossi S, Tabolacci C, Nikolic J, Sokolovic D,
Bjelakovic L. 2010. Metabolic correlations of glucocorti-
coids and polyamines in inflammation and apoptosis.
Amino Acids. 39:29–43.
Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV.
2015. Molecular mechanisms of antibiotic resistance. Nat
Rev Microbiol. 13:42–51.
Borriello G, Werner E, Roe F, Kim AM, Ehrlich GD, Stewart PS.
2004. Oxygen limitation contributes to antibiotic tolerance
CRITICAL REVIEWS IN MICROBIOLOGY 183
of Pseudomonas aeruginosa in biofilms. Antimicrob Agents
Chemother. 48:2659–2664.
Bragonzi A, Farulla I, Paroni M, Twomey KB, Pirone L, Lore NI,
Bianconi I, Dalmastri C, Ryan RP, Bevivino A. 2012.
Modelling co-infection of the cystic fibrosis lung by
Pseudomonas aeruginosa and Burkholderia cenocepacia
reveals influences on biofilm formation and host response.
PLoS One. 7:e52330.
Brauner A, Fridman O, Gefen O, Balaban NQ. 2016.
Distinguishing between resistance, tolerance and persist-
ence to antibiotic treatment. Nat Rev Microbiol. 14:
320–330.
Brooun A, Liu SH, Lewis K. 2000. A dose-response study of
antibiotic resistance in Pseudomonas aeruginosa biofilms 1.
Antimicrob Agents Chemother. 44:640–646.
Bush K. 2010. Bench-to-bedside review: the role of beta-lac-
tamases in antibiotic-resistant Gram-negative infections.
Crit Care. 14:224.
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